{"disease":{"id":"moderate-essential-hypertension","name":"moderate essential hypertension"},"drugs":{"marketed":[{"drug_id":"mecamylamine","indication_name":"Moderately severe to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inversine","generic_name":"MECAMYLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha3/beta2","drug_class":"Autonomic Ganglionic Blocker","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"mecamylamine-hydrochloride","indication_name":"Moderate to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MECAMYLAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06771245","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":606,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}